CDK1 and neoplasm: These findings suggest that CDK1-expressing cells may contribute to the suppressive immune microenvironment and promote the proliferation of tumor cells and angiogenesis of tumors by secreting MDK and SPP1 into the TME; these ideas partially explain why patients with LUAD with high CDK1 expression benefit little from immunotherapy and have poor survival.